Dopson Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 08-07-2024
- Paid Up Capital ₹ 6.00 Cr
as on 08-07-2024
- Company Age 42 Year, 9 Months
- Last Filing with ROC 31 Mar 2018
- Satisfied Charges ₹ 9.13 M
as on 08-07-2024
- Revenue %
(FY 2018)
- Profit -54416.71%
(FY 2018)
- Ebitda -54416.71%
(FY 2018)
- Net Worth -99.95%
(FY 2018)
- Total Assets -99.95%
(FY 2018)
About Dopson Pharma (India)
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 6.00 Cr.
The company has closed loans amounting to ₹9.13 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Anil Mangal, Chetan Palikar, and Kuldeep Agrawal serve as directors at the Company.
- CIN/LLPIN
U99999MH1982PLC026712
- Company No.
026712
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
19 Mar 1982
- Date of AGM
30 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dopson Pharma (India)?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Mangal  | Additional Director | Current | |
| Chetan Palikar | Additional Director | 27-Jun-2007 | Current |
| Kuldeep Agrawal | Director | Current |
Financial Performance of Dopson Pharma (India).
Dopson Pharma (India) Limited, for the financial year ended 2018, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 54416.71% decrease in profit. The company's net worth observed a substantial decline by a decrease of 99.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dopson Pharma (India)?
In 2018, Dopson Pharma (India) had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
New World Medical (India) LimitedActive 55 years 9 monthsAnil Mangal, Chetan Palikar and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Corporation Bank Creation Date: 09 Mar 2000 | ₹8.50 M | Satisfied |
Canara Bank Creation Date: 10 Mar 1986 | ₹0.18 M | Satisfied |
Canara Bank Creation Date: 10 Mar 1983 | ₹0.30 M | Satisfied |
How Many Employees Work at Dopson Pharma (India)?
Unlock and access historical data on people associated with Dopson Pharma (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dopson Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dopson Pharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
